Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.67 |
| ▸ | CHEK2 | O96017 | 5/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 10/20 | 0.56 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.55 |
| ▸ | USP7 | Q93009 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19822287 | 0.87 | MAPK1 (0.70) | MAPK1CHEK2MAP4K4MKNK1FYN | |
| SCHEMBL19822286 | 0.86 | MAPK1 (0.71) | MAPK1CHEK2 | |
| SCHEMBL16679393 | 0.80 | MAPK1 (1.00) | MAPK1CHEK2MAP4K4 | |
| SCHEMBL19813060 | 0.80 | MAPK1 (1.00) | MAPK1CHEK2MAP4K4 | |
| SCHEMBL19822270 | 0.79 | MAPK1 (0.70) | MAPK1 | |
| SCHEMBL19822288 | 0.78 | MAPK1 (0.71) | MAPK1 | |
| SCHEMBL19822290 | 0.75 | MAPK1 (0.73) | MAPK1 | |
| SCHEMBL19822303 | 0.75 | MAPK1 (0.72) | MAPK1CHEK2MAP4K4MKNK1 | |
| SCHEMBL20145620 | 0.74 | MAPK1 (0.70) | MAPK1CHEK2MAP4K4MKNK1 | |
| SCHEMBL19822305 | 0.74 | MAPK1 (0.74) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028532-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028532-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | MAPK1 95/4885CHEK2 180/4885MAP4K4 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.